Association between plasma lipoprotein(a) concentration and restenosis after stent implantation

Circulation Journal

Volumn 69, Issue 6, 2005, Pages 644-649

  Kamitani, Tadaaki ^a   Taniguchi, Takuya ^a   Miyai, Nobuyuki ^a   Kawasaki, Tatsuya ^a   Kawasaki, Shingo ^a   Sugihara, Hiroki ^a  

^a MATSUSHITA MEMORIAL HOSPITAL   (Japan)

Author keywords

In stent restenosis; Lesion length; Lipoprotein (a); Reference diameter; Stent implantation

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPOPROTEIN; NITRATE; STATINE DERIVATIVE; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; CORONARY ARTERY; CORONARY STENT; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; RESTENOSIS; STATISTICAL MODEL;

AGED; BIOLOGICAL MARKERS; CORONARY RESTENOSIS; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; STENTS;

EID: 20444366614     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.69.644     Document Type: Article

References (40)

1. Holmes DR Jr, Vlietstra RE, Smith HC, Vertrovec GW, Kent KM, Cowley MJ, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984; 53: 71C-81C.
2. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand, et al. Incidence of restenosis after successful coronary angioplasty: A time-related phenomenon: A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77: 361-371.
3. Nobuyoshi M, Kimura T, Nosaka H, Ueno K, Yokoi H, Hamasaki N, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988; 12: 616-623.
4. Fischeman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigations. N Engl J Med 1994; 331: 496-501.
5. Serruy PW, Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent group. N Engl J Med 1994; 331: 489-495.
6. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risk associated with lipoprotein (a). Nature 1989; 339: 301-303.
7. Haijjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein (a) modulation of endothelial cell surface and its potential role in atherosclerosis. Nature 1989; 339: 303-305.
8. Schwartzman RA, Cox ID, Poloniecki J, Crook R, Seymour CA, Kaski JC. Elevated plasma lipoprotein (a) is associated with coronary artery disease in patients with chronic stable angina pectoris. J Am Coll Cardiol 1998; 31: 1260-1266.
9. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease: Meta-analysis of prospective studies. Circulation 2000; 102: 1082-1085.
10. Stubbs P, Seed M, Lane D, Collinson P, Kendall F, Noble M. Lipoprotein (a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J 1998; 19: 1355-1364.
11. Pay S, Ozean N, Tokgozogle SL. Elevated Lp(a) is the most frequent familial lipoprotein disorder leading to premature myocardial infarction in a country with low cholesterol levels. Int J Cardiol 1997; 60: 301-305.
12. Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS. Predictive value of electrophoretically detected lipoprotein (a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997; 96: 1390-1397.
13. Maca T, Ahmadi R, Derfler K, Horl WH, Koppensteiner R, Minar E, et al. Elevated lipoprotein (a) and increased incidence of restenosis after femoropopliteal PTA: Rationale for the higher risk of recurrence in females? Atherosclerosis 1996; 127: 27-34.
14. Von Depka M, Nowak-Gotti U, Eisert R, Dieterich C, Barthels M, Scharrer I, et al. Increased lipoprotein (a) level as an independent risk factor for venous thromboembolism. Blood 2000; 96: 3364-3368.
15. Linden T, Taddei-Peters W, Wilhelmsen L, Herlitz J, Karlsson T, Ullstrom C, et al. Serum lipids, lipoprotein (a) and apo (a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. Atherosclerosis 1998; 137: 175-186.
16. Miyata M, Biro S, Arima S, Hamasaki S, Kaieda H, Hakao S, et al. High serum concentration of lipoprotein (a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Am Heart J 1996; 132: 269-273.
17. Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein (a) is a risk factor for clinical recurrence after coronary angioplasty. Circulation 1995; 91: 1403-1409.
18. Horie H, Takahashi M, Izumi M, Takaoka A, Fujita T, Sakamoto T, et al. Association of an acute reduction in lipoprotein (a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty. Circulation 1997; 96: 166-173.
19. Schumacheer M, Tiran A, Eber B, Toplak H, Wilders-Truschnig M, Klein W. Lipoprotein (a) is not a risk factor for restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992; 69: 572.
20. Alaigh P, Hoffman CJ, Korlipara G, Neuroth A, Dervan JP, Lawson WE, et al. Lipoprotein (a) level does not predict restenosis after percutaneous transluminal coronary angioplasty. Arterioscler Thromb Vasc Biol 1998; 18: 1281-1286.
21. Ribichini F, Steffenino G, Dellavalle A, Vado A, Ferrero V, Camilla T, et al. Plasma lipoprotein (a) is not a predictor for restenosis after elective high-pressure coronary stenting. Circulation 1998; 98: 1172-1177.
22. Dangas G, Mehran R, Harpel PC, Sharma SK, Marcovina SM, Dube G, et al. Lipoprotein (a) and inflammation in human coronary atheroma: Association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32: 2035-2042.
23. Mancini GB, Simon SB, McGillen MJ, Lefree MT, Friedman HZ, Vogel RA. Automated quantitative coronary arteriography: Morphologic and physiologic validation in vivo of a rapid digital angiographic method. Circulation 1987; 75: 452-460.
24. Abe A, Maeda S, Makino K, Seishima M, Shimokawa K, Noma A, et al. Enzyme-linked immunosorbent assay of lipoprotein (a) in serum and cord blood. Clin Chim Acta 1988; 177: 31-40.
25. Abe A, Noma A. Studies on apolipoprotein (a) phenotypes: Part 1: Phenotype frequencies in a healthy Japanese population. Atherosclerosis 1992; 96: 1-8.
26. Roubin GS, Cannon AD, Agrawal SK, Macander PJ, Dean LS, Baxlay WA, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992; 85: 916-927.
27. Schwantzs RS. Pathophysiology of restenosis: Interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol 1998; 81: 14E-17E.
28. Liu MW, Roubin GS, King SB 3rd. Restenosis after coronary angioplasty: Potential biologic determinants and role of intimal hyperplasia. Circulation 1989; 79: 1374-1387.
29. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, et al. Arterial remodeling after coronary angioplasty: A serial intravascular ultrasound study. Circulation 1996; 94: 35-43.
30. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells prompted by lipoprotein (a). Science 1993; 260: 1655-1658.
31. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in human: Macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98: 224-233.
32. Iijima R, Ikari Y, Miyazawa A, Nakajima H, Hara K. Predictors of restenosis after implantation of 2.5 mm stent in small coronary arteries. Circ J 2004; 68: 236-240.
33. Biemond BJ, Friedrich PW, Koschinsky ML, Levi M, Sangrar W, Xia J, et al. Apolipoprotein (a) attenuates endogeneous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation 1997; 96: 1612-1615.
34. Grainger DJ, Metcalfe JC. Transforming growth factor-beta: The key to understanding lipoprotein (a)? Curr Opin Lipidol 1995; 6: 81-85.
35. Miyata M, Briro S, Kaieda H, Tanaka H. Lipoprotein (a) stimulates the proliferation of cultured human arterial smooth muscle cells through two pathways. FEBS Lett 1995; 377: 493-496.
36. Kanemitsu S, Takekoshi N, Matsui S, Tsugawa H, Ohkubo S, Kitayama M, et al. Short-term and long-term effects of low-density lipoprotein (LDL) apheresis on restenosis after percutaneous transluminal coronary angioplasty (PTCA): Is lowering Lp(a) by LDL apheresis effective on restenosis after PTCA? Ther Apher 1998; 2: 65-70.
37. Igarashi Y, Aizawa Y, Satoh T, Konno T, Ojima K, Aizawa Y. Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty: With special reference to the admission concentration of lipoprotein (a) Circ J 2003; 67: 605-611.
38. Fujino A, Watanabe T, Kunii H, Yamaguchi N, Yoshinari K, Watanabe Y, et al. Lipoprotein (a) is a potential coronary risk factor. Jpn Circ J 2000; 64: 51-56.
39. Budde T, Fechtrup C, Bosenberg E, Vielhauer C, Enbergs A, Schulte H, et al. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb 1994; 14: 1730-1736.
40. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein (a) as an acute phase protein. Atherosclerosis 1989; 78: 145-150.